Novartis AG (NYSE:NVS) Shares Purchased by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. raised its holdings in shares of Novartis AG (NYSE:NVS) by 12.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,171 shares of the company’s stock after purchasing an additional 679 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novartis were worth $600,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NVS. Integral Health Asset Management LLC grew its position in shares of Novartis by 33.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock worth $31,938,000 after acquiring an additional 75,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Novartis by 115.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after acquiring an additional 124,111 shares in the last quarter. Bank of Montreal Can grew its position in shares of Novartis by 343.5% in the 2nd quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock worth $70,652,000 after acquiring an additional 509,567 shares in the last quarter. CWA Asset Management Group LLC grew its position in shares of Novartis by 20.1% in the 4th quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after acquiring an additional 5,164 shares in the last quarter. Finally, Quantbot Technologies LP grew its position in shares of Novartis by 135.5% in the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after acquiring an additional 22,998 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Down 1.2 %

Shares of NYSE NVS opened at $99.06 on Friday. The stock’s 50 day simple moving average is $101.55 and its 200 day simple moving average is $109.26. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market cap of $202.48 billion, a price-to-earnings ratio of 11.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same quarter in the previous year, the business earned $1.74 EPS. Equities research analysts expect that Novartis AG will post 7.65 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NVS shares. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.